NCT05989828View on ClinicalTrials.gov

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 17, 2024

Primary Completion Date

December 17, 2026

Study Completion Date

December 17, 2027

Conditions
Triple Negative Breast Cancer
Interventions
BIOLOGICAL

Aldesleukin

Given IV

BIOLOGICAL

Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes

Given IV

PROCEDURE

Biopsy

Undergo biopsy of breast tumor

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT scan

DRUG

Cyclophosphamide

Given IV

PROCEDURE

Echocardiography

Undergo ECHO

DRUG

Fludarabine

Given IV

PROCEDURE

Leukapheresis

Undergo leukapheresis

PROCEDURE

Magnetic Resonance Imaging

Undergo breast MRI

PROCEDURE

Mammogram

Undergo mammogram

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA scan

PROCEDURE

Ultrasound Imaging

Undergo ultrasound of breast

Trial Locations (1)

90033

RECRUITING

USC / Norris Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER